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tion (whatever this refers to), employment and insurance. Indeed,
such individuals were invited to the conference as well as individ-
uals representing government, industry, and even the WHO.
Many of these groups responded and had input into the final
document.
Content of the revised definition of myocardial infarction. Dr.
Tunstall-Pedoe misinterprets the final document. In the report,
the definition of myocardial infarction rests on elevated blood
troponin or CK-MB levels in an appropriate clinical setting.
Patients who arrive at the hospital 24 or 48 h after the onset of
their infarct will still have an elevated troponin level that remains
abnormal for 3 to 14 days following the onset of myocardial
necrosis. Therefore, such late-arriving patients as described by Dr.
Tunstall-Pedoe will meet the new definition of myocardial infarc-
tion. Patients with infarction who are first seen many days, weeks
or months after their infarction can still meet the diagnosis for
“established infarction” as noted in the published ESC/ACC
document.
The patient who dies shortly after arriving in the coronary care
unit represents a problem for diagnosis of myocardial infarction.
This is true today and will remain true in the future. As pointed
out by the pathology group in the published ESC/ACC document,
infarction cannot be recognized pathologically until at least 6 h has
passed since the onset of ischemia/infarction. Thus, there is
currently a window of “blindness” for the diagnosis of infarction
that lasts for approximately 6 h after the onset of myocardial
necrosis. Abnormal CK-MB levels may be seen as early as 3 to 4 h
after the onset of necrosis and abnormal blood myoglobin levels
may be observed even earlier. Perhaps, subsequent revised editions
of the ESC/ACC report will contain suggestions about diagnosis
of infarction in the early few hours after the onset of myocardial
necrosis. Further data will be needed before any such suggestion
can be made. In addition, patients with unequivocal ECG evidence
(pathologic Q-waves) for infarction but no serological assays can
still be labeled as having had an infarct based on the criteria for
“established infarction.”
Even though the enzyme assays are not standardized in the
original WHO and derived MONICA criteria, Dr. Tunstall-
Pedoe vigorously defends the MONICA definition for the diag-
nosis of myocardial infarction (1). This is understandable, but may
be ill-advised given the recent report of Porela et al. (2) that failed
to document prognostic significance associated with this method
for diagnosing infarction. Indeed, Dr. Tunstall-Pedoe states that
the MONICA investigators have been seriously considering revis-
ing their own definition of myocardial infarction. This is com-
mendable given the recently published data cited above.
We welcome Dr. Tunstall-Pedoe’s suggestion that the new
definition be “field tested,” and indeed, a number of investigators
are already proceeding with such studies. As noted already, the
data of Porela et al. (2) support the concept of myocardial
infarction defined by means of abnormal blood levels of a myo-
cardial enzyme, CK-MB. These same investigators failed to find
similar supportive data for the MONICA definition of infarction.
We anxiously await the results of further “field testing.”
The unfortunate fact is that the “new” definition of myocardial
infarction was already being widely used before our meeting in
Nice, France, took place. Indeed, many hospitals and many
clinicians around the world already define myocardial infarction
based on an abnormal blood troponin value. It was this fact, and
the resulting confusion created between hospitals and physicians
who used the new sensitive and specific cardiac markers versus
those who did not, that led us to organize the ESC/ACC
consensus conference. Thus, the “confusion and chaos” referred to
by Dr. Tunstall-Pedoe were already present when we began
sending out invitations to the meeting at the European Heart
House.
In conclusion, we believe that the process as well as the product
that led to the ESC/ACC new definition for myocardial infarction
were both fair, reasonable and represented the opinion of most of
the participants at the ESC/ACC conference as well as a variety of
experts who subsequently examined the manuscript and made
useful comments. We look forward to further work in this area that
will undoubtedly result in revisions to the currently recommended
definition for myocardial infarction.
Joseph S. Alpert, MD, FACC, FESC
Department of Internal Medicine
University of Arizona
1501 North Campbell Avenue
Tucson, Arizona 85724
Kristian Thygesen, MD, FACC, FESC
PII S0735-1097(01)01153-6
REFERENCES
1. Tunstall-Pedoe H, Kuulasmaa K, Amouyel P, Arveiler D, Rajakangas
AM, Pajak A. Myocardial infarction and coronary deaths in the World
Health Organization MONICA Project: Registration procedures, event
rates, and case-fatality rates in 38 populations from 21 countries in four
continents. Circulation 1994;90:583–612.
2. Porela P, Helenius H, Pulkki K, Voipio-Pulkki L-M. Epidemiological
classification of acute myocardial infarction: time for a change? Eur
Heart J 1999;20:1459–64.
Benefit of Aspirin Plus
Angiotensin-Converting Enzyme Inhibitor
The conclusions of your recent editorial commentary (1) on a
meta-analysis (2) of the trials of angiotensin-converting enzyme
(ACE) inhibitors in acute myocardial infarction (MI) go far
beyond the randomized evidence and could well be mistaken. As
treatments for acute MI, aspirin substantially improves survival (3)
and ACE inhibitors moderately improve survival (2,4). The trials
of aspirin were done at a time when ACE inhibitors were not
routinely used in acute MI, and demonstrated the substantial
effectiveness of aspirin. The trials of ACE inhibitors were done
more recently, at a time when aspirin was already widely used in
acute MI, and the meta-analysis of their results showed that the
addition of ACE inhibitors produced a small but significant
additional benefit: that is, that aspirin 1 ACE inhibitors produce
slightly better survival than aspirin alone (2). It was concluded that
aspirin is of value in the treatment of acute MI, and that the
combination of aspirin 1 ACE inhibitors is slightly but signifi-
cantly better than aspirin alone. A similar conclusion was sug-
gested by meta-analyses of the trials of long-term aspirin therapy
(3) and of the trials of long-term ACE inhibitor therapy (5);
aspirin is of value, but the combination of aspirin 1 ACE
inhibitors is somewhat better than aspirin alone.
In the trials of ACE inhibitors both during and after MI, there
was no significant interaction between the presence of aspirin and
the efficacy of ACE inhibitors (2,5), and it was a bizarre non-
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sequitur for your editorial commentary on these trials convolutedly
to conclude that many patients receiving long-term ACE inhibi-
tors should be denied the proven benefits of long-term aspirin
therapy in exchange for the less clearly proven benefits of other
antiplatelet agents.
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REPLY
Thank you for your comments. At issue is not primarily the
long-term effects of aspirin in coronary artery disease but its
combination with an angiotensin-converting enzyme (ACE) in-
hibitor in patients with heart failure (1). Any real benefits of
long-term aspirin therapy, however, have been regarded, at best, as
questionable. The meta-analysis (1) on which your argument is
based is characterized by important weaknesses and shortcomings
which Dr. Cleland has done a good job of pointing out (2).
I am sure that no responsible physician wants to deny patients
drugs of proven benefit. However, the negation of an interaction (3)
based on results of the use of otherwise effective heart failure drugs
which, in 90,000 patients taking the combination of an ACE
inhibitor with aspirin, did conspicuously little or nothing is a
benefit with which some physicians are not content. There was not
even prevention of heart failure. Moreover, in the most recent
meta-analysis cited (4) in your letter in which, similar to that of
Latini et al. (3), the patient groups are dissimilar, there was a
consistently more favorable risk reduction in patients without
aspirin (0.85 vs. 0.75 and 0.76 vs. 0.68 for death and combined
death, heart failure and myocardial infarction in the aspirin vs. no
aspirin groups, respectively). Consequently, in consideration of the
comparative yield of the combination of an ACE inhibitor and
aspirin and an ACE inhibitor without aspirin (Table 1 of reference
[5]), it appears, rather, that with the combination, we are denying
many patients an effective treatment for heart failure.
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Papillary Muscle Hypothesis of
Idiopathic Left Ventricular Tachycardia
Nogami et al. (1) recently demonstrated that diastolic (P1) and
presystolic (P2) Purkinje potentials are critical potentials in a
macroreentry circuit of verapamil-sensitive idiopathic left ventric-
ular tachycardia. The authors posit that P1 represents the activa-
tion potential in the distal portion of the specialized Purkinje tissue
and P2 represents the activation potential of the left posterior
fascicle. There was no mentioning of the papillary muscle as a
possible source of these potentials.
In most parts of the ventricular endocardium, Purkinje poten-
tials and myocardial potentials are nonseparable. This is not true at
the papillary muscle, where Purkinje potentials and ventricular
muscle potentials are widely separated (2,3). Joyner et al. (2)
reported that pacing from a Purkinje strand inserting into the apex
of the papillary muscle results in apex to base Purkinje activation.
The activation then excites the ventricular muscle via the Purkinje
ventricular muscle junction at the base of the papillary muscle, and
propagates from base of the papillary muscle to the apex of the
papillary muscle. The resulting activation sequence shown in
Figure 1B of that article is identical to the sequence of activation
shown in Figure 2 of the study of Nogami et al. (1). The Purkinje
strands (fibromuscular band or false tendon), which are often seen
in dogs, are also found commonly in humans, especially among
patients with idiopathic left ventricular tachycardia (4).
The safety factor of propagation from Purkinje to ventricular
muscle is lower than that from the ventricular muscle to the
Purkinje fibers (2,5). This asymmetrical safety factor of propaga-
tion may contribute to the occurrence of unidirectional block and
reentry. The papillary muscle may serve as an anchor to reentrant
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